Neuromuscular blocking agents

I. Introduction

Neuromuscular blocking agents (NMBAs) are a class of drugs used to induce temporary skeletal muscle paralysis by blocking transmission at the neuromuscular junction (NMJ). They are indispensable in anesthesia, intensive care, and emergency medicine, facilitating endotracheal intubation, mechanical ventilation, and surgical procedures requiring muscle relaxation.

NMBAs work by inhibiting the action of acetylcholine (ACh) at nicotinic receptors on skeletal muscle. They do not affect consciousness, sensation, or pain; thus, they must always be used in combination with adequate sedation and analgesia.

They are categorized into two pharmacological groups:

1. Depolarizing neuromuscular blockers

2. Non-depolarizing neuromuscular blockers

---

II. Neuromuscular Junction: Target Site of NMBAs

The neuromuscular junction (NMJ) is a synapse between a motor neuron and a skeletal muscle fiber, where:

• ACh is released from presynaptic nerve terminals

• ACh binds to nicotinic ACh receptors (nAChRs) on the postjunctional muscle membrane

• This causes muscle depolarization and contraction

NMBAs block this process by:

• Either mimicking ACh and overstimulating the receptor (depolarizing)

• Or competing with ACh without activating the receptor (non-depolarizing)

---

III. Classification of Neuromuscular Blocking Agents

Class	Mechanism	Duration	Reversal
Depolarizing	Agonist at nAChRs → persistent depolarization	Ultra-short	No pharmacologic reversal
Non-depolarizing	Competitive antagonist at nAChRs	Short to long	Neostigmine, Sugammadex

IV. Depolarizing Neuromuscular Blockers

Succinylcholine (Suxamethonium)

• Mechanism: Binds to nAChRs → causes initial depolarization (fasciculations) → sustained depolarization → muscle paralysis

• Onset: 30–60 seconds

• Duration: 5–10 minutes (ultra-short)

• Metabolism: Rapid hydrolysis by plasma pseudocholinesterase

• Clinical use: Rapid sequence intubation (RSI), short procedures

Adverse Effects:

• Hyperkalemia (especially in burns, trauma, neuromuscular disease)

• Malignant hyperthermia (genetic susceptibility)

• Bradycardia (via muscarinic stimulation)

• Prolonged apnea in pseudocholinesterase deficiency

• Fasciculations and postoperative myalgia

• Increased intraocular and intracranial pressure

Contraindications:

• History of malignant hyperthermia

• Muscular dystrophy, spinal cord injuries

• Hyperkalemia or renal failure

---

V. Non-Depolarizing Neuromuscular Blockers

Mechanism: Competitively block ACh from binding to nicotinic receptors, preventing depolarization and muscle contraction.

Reversal: Most are reversible with acetylcholinesterase inhibitors (e.g., neostigmine) or selective binding agents (e.g., sugammadex for rocuronium and vecuronium).

Short-Acting (≤30 mins)

• Mivacurium: Rapidly hydrolyzed by plasma cholinesterase

Intermediate-Acting (30–60 mins)

• Rocuronium: Rapid onset, ideal for RSI; reversed by sugammadex

• Vecuronium: Minimal cardiovascular effects, hepatic clearance

• Atracurium: Undergoes Hofmann elimination (non-organ dependent)

• Cisatracurium: More potent stereoisomer of atracurium, fewer side effects

Long-Acting (>60 mins)

• Pancuronium: Long duration, vagolytic (↑ HR); renal elimination

• Doxacurium: Long-acting, rare use

Key differences among agents:

Agent	Onset	Duration	Elimination	Special Notes
Rocuronium	1–2 min	30–45 min	Hepatic	Reversed by sugammadex
Vecuronium	2–3 min	30–40 min	Hepatic/Renal	Minimal CV effects
Atracurium	2–3 min	20–35 min	Hofmann + esterase	Histamine release
Cisatracurium	2–3 min	30–40 min	Hofmann elimination	Preferred in organ failure
Pancuronium	3–5 min	60–90 min	Renal	Increases heart rate

VI. Monitoring Neuromuscular Blockade

Neuromuscular transmission is monitored using peripheral nerve stimulators, often via the train-of-four (TOF) technique:

• TOF ratio < 0.9 indicates residual blockade

• Ensures adequate reversal before extubation

• Helps titrate dosing in ICU to prevent prolonged paralysis

---

VII. Clinical Uses

1. Anesthesia

   • Muscle relaxation for surgery

   • Tracheal intubation

   • Abdominal or thoracic operations

2. Critical Care / ICU

   • Facilitate mechanical ventilation

   • Manage severe ARDS

   • Reduce oxygen consumption in sepsis

   • Control intracranial pressure

3. Emergency Medicine

   • Rapid Sequence Intubation (RSI)

   • Trauma cases

4. Electroconvulsive Therapy (ECT)

   • Prevent injury due to convulsions (e.g., succinylcholine)

---

VIII. Adverse Effects

Type	Effect
Muscular	Prolonged weakness, myopathy (especially in ICU)
Cardiovascular	Bradycardia (succinylcholine), tachycardia (pancuronium)
Histamine release	Hypotension, bronchospasm (atracurium, mivacurium)
Electrolyte	Hyperkalemia (succinylcholine)
Other	Malignant hyperthermia, anaphylaxis

IX. Drug Interactions

Interacting Drug Class	Effect on NMBAs
Aminoglycosides	Potentiate blockade (inhibit ACh release)
Magnesium sulfate	Enhances blockade
Local anesthetics	Increase NMBA effect
Corticosteroids	Long-term use → critical illness myopathy
Phenytoin	Chronic use may decrease NMBA efficacy
Lithium	Enhances both depolarizing and non-depolarizing effects

X. Reversal of Neuromuscular Blockade

1. Acetylcholinesterase Inhibitors:

• Neostigmine, Edrophonium

• Inhibit breakdown of ACh → ↑ ACh competes with NMBA

• Co-administer with antimuscarinic (e.g., atropine or glycopyrrolate) to counter bradycardia

2. Sugammadex:

• Specific to aminosteroidal NMBAs (rocuronium, vecuronium)

• Forms tight complexes and inactivates them

• Rapid and complete reversal even of deep blockade

• Adverse effects: bradycardia, anaphylaxis (rare), expensive

---

XI. Contraindications and Special Populations

• Succinylcholine:

  • Avoid in: burns >48h, neuromuscular diseases, crush injuries, children (routine use), glaucoma

• Non-depolarizing agents:

  • Dose adjust in renal or hepatic failure (agent-specific)

  • Monitor closely in elderly, cachectic, or obese patients

---

XII. Clinical Pearls

• Always use sedation with NMBAs—these drugs do not induce unconsciousness or analgesia

• In the ICU, prolonged use increases risk of critical illness polyneuropathy/myopathy

• Use neuromuscular monitoring to titrate dose and guide reversal

• Choose cisatracurium or atracurium in patients with multi-organ failure due to organ-independent elimination

---

XIII. Summary of Common Neuromuscular Blocking Agents

Drug	Type	Duration	Elimination	Reversible by Sugammadex?
Succinylcholine	Depolarizing	Ultra-short	Pseudocholinesterase	No
Rocuronium	Non-depolarizing	Intermediate	Hepatic	Yes
Vecuronium	Non-depolarizing	Intermediate	Hepatic/Renal	Yes
Atracurium	Non-depolarizing	Intermediate	Hofmann	No
Cisatracurium	Non-depolarizing	Intermediate	Hofmann	No
Pancuronium	Non-depolarizing	Long	Renal	No